Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future
Karlyne M. Reilly; AeRang Kim; Jaishri Blakely; Rosalie E. Ferner; David H. Gutmann; Eric Legius; Markku M. Miettinen; R. Lor Randall; Nancy Ratner; N. L. Jumbé; Annette Bakker; David Viskochil; Brigitte C. Widemann; Douglas R. Stewart
Author Information: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children’s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital London, London, UK (REF); Department of Neurology, Washington University School of Medicine, St. Louis, MO (DHG); Department of Human Genetics, University of Leuven, Leuven, Belgium (EL); Hunstman Cancer Institute, University of Utah, Salt Lake City, UT (RLR, DV); Division of Experimental Hematology and Cancer Biology, Department of Pediatrics, Cincinnati Children’s Hospital, University of Cincinnati, Cincinnati, OH (NR); Bill and Melinda Gates Foundation, Seattle, WA (NLJ); Children’s Tumor Foundation, New York, NY (AB); Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD (DRS).
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.